Cancer Vaccine for Solid Cancers

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: NantBioScience, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?This is a phase 1 study to evaluate the safety, the Recommended Phase 2 Dose (RP2D), and preliminary efficacy of a personalized neoepitope yeast-based vaccine, YE-NEO-001, in subjects who have completed potentially curative therapy for their solid cancer and who would otherwise be entering a period of surveillance for recurrent disease.

Eligibility Criteria

This trial is for adults who've had surgery or other curative treatments for certain solid cancers (like colorectal, breast, lung cancer, etc.) and are now in a surveillance period with no evidence of disease. They must be able to provide tissue samples, have an ECOG status of 0-2, and agree to use effective contraception.

Inclusion Criteria

Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines

My cancer can be treated with the intention to cure, as per standard care.

I am willing to give a tumor tissue and blood sample for testing.

+11 more

Exclusion Criteria

My lab results show my organs are not functioning well.

Positive results of screening test for HIV

I am willing and able to follow the study's requirements.

+12 more

Participant Groups

The study tests YE-NEO-001, a personalized neoepitope yeast-based vaccine designed to trigger T-cell responses against cancer. It's given after standard treatment when patients are monitoring for recurrence. The goal is to find the safest dose and see if it helps prevent cancer from coming back.

1Treatment groups

Experimental Treatment

Group I: Experimental: NANT Neoepitope Yeast Vaccine (YE-NEO-001)Experimental Treatment1 Intervention